AXGN vs. BLFS, ZYXI, EDAP, SMLR, OM, ELMD, FONR, VANI, HYPR, and CUTR
Should you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include BioLife Solutions (BLFS), Zynex (ZYXI), Edap Tms (EDAP), Semler Scientific (SMLR), Outset Medical (OM), Electromed (ELMD), FONAR (FONR), Vivani Medical (VANI), Hyperfine (HYPR), and Cutera (CUTR). These companies are all part of the "electromedical equipment" industry.
AxoGen (NASDAQ:AXGN) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.
AxoGen has a net margin of -12.99% compared to BioLife Solutions' net margin of -45.84%. BioLife Solutions' return on equity of -12.89% beat AxoGen's return on equity.
80.3% of AxoGen shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 7.0% of AxoGen shares are owned by company insiders. Comparatively, 2.7% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
AxoGen has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500.
AxoGen has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than AxoGen, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioLife Solutions had 8 more articles in the media than AxoGen. MarketBeat recorded 8 mentions for BioLife Solutions and 0 mentions for AxoGen. BioLife Solutions' average media sentiment score of 0.36 beat AxoGen's score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the news media.
AxoGen received 144 more outperform votes than BioLife Solutions when rated by MarketBeat users. Likewise, 72.48% of users gave AxoGen an outperform vote while only 66.74% of users gave BioLife Solutions an outperform vote.
AxoGen currently has a consensus price target of $10.67, suggesting a potential upside of 51.52%. BioLife Solutions has a consensus price target of $23.67, suggesting a potential upside of 14.00%. Given AxoGen's higher possible upside, equities analysts plainly believe AxoGen is more favorable than BioLife Solutions.
Summary
AxoGen beats BioLife Solutions on 9 of the 17 factors compared between the two stocks.
Get AxoGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
